Quantcast

Latest Histone deacetylase Stories

2011-01-11 13:29:00

WALTHAM, Mass., Jan. 11, 2011 /PRNewswire/ -- Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research. "These findings demonstrate the promise for epigenetic...

2010-12-10 17:30:00

WALTHAM, Mass., Dec. 10, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas. The following poster discussions...

2010-12-07 13:49:00

In a study published in the journal Developmental Cell, Sarah Millar PhD, professor of Dermatology and Cell & Developmental Biology at the University of Pennsylvania School of Medicine, and colleagues demonstrate that a pair of enzymes called HDACs are critical to the proper formation of mammalian skin. The findings, Millar says, not only provide information about the molecular processes underlying skin development, they also suggest a potential anticancer strategy. "Inhibition of these...

2010-12-07 07:00:00

SINGAPORE, Dec. 7, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from a Phase 1 study for its oral histone deacetylase (HDAC) Inhibitor SB939 showed tolerability and safety in patients with advanced hematologic malignancies. Results were presented at the 52nd ASH Annual Meeting and Exposition in Orlando, Fla. "SB939 was well tolerated with limited toxicities and demonstrated excellent pharmacokinetic properties in patients with hematologic malignancies," said Guillermo...

2010-11-01 21:38:57

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves a substantial number of patients without a cure. However, a team of researchers, led by Ari Melnick, at Weill Cornell Medical College, New York, has now identified a potential new combinatorial therapy for DLBCL. Specifically, the team found that combining an inhibitor of the protein BCL6 with either an...

2010-10-25 16:06:03

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. In their study, researchers at The University of Texas MD Anderson Children's Cancer Hospital in Houston found that blocking the Notch pathway in mice decreased metastases in the lungs 15-fold. The results of a series of pre-clinical studies were reported Sunday in an oral presentation at the 42nd Congress of the International Society of Pediatric...

2010-10-15 07:30:00

WALTHAM, Mass., Oct. 15 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B. The patent covers the polymorph representing a preferred stable form of entinostat (SNDX-275 formerly MS-275) with key claims covering the polymorph form B and the manufacturing...

2010-10-08 14:38:44

Heart muscle cells do not normally replicate in adult tissue, but multiply with abandon during development. This is why the loss of heart muscle after a heart attack is so dire"”you can't grow enough new heart muscle to make up for the loss. A team of researchers at the University of Pennsylvania School of Medicine describe the interconnections between three-molecules that control fetal, heart-muscle-cell proliferation in a mouse model that will help cardiologists better understand the...

2010-09-27 06:00:00

SINGAPORE, Sept. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). The trial is sponsored by the NCIC Clinical Trials Group and will be conducted at eight clinical sites in Canada. Sixty milligrams of SB939 will be administered orally three times per week, on alternate days, for three consecutive weeks followed by one week off drug....

2010-08-11 07:30:00

WALTHAM, Mass., Aug. 11 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering. "Our investors continue to demonstrate strong...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related